ADVFN Logo ADVFN

Hot Features

Registration Strip Icon for charts 登録してリアルタイムのチャート、分析ツール、価格を入手してください。
9.52
0.03
(0.32%)
終了 11月14日 6:00AM
9.5499
0.0299
(0.31%)
取引時間後: 9:58AM

個人投資家向けのプロ仕様のツール。

主要統計と詳細

通貨
9.5499
買値
9.52
売値
9.55
出来高
9,912,142
9.46 日の範囲 11.16
2.315 52 週間の範囲 14.84
時価総額
前日終値
9.49
始値
9.64
最終取引時間
財務取引量
US$ 100,989,165
VWAP
10.1884
平均取引量 (3 か月)
2,408,808
発行済株式数
71,070,951
配当利回り
-
PER
-7.64
1 株当たり利益 (EPS)
-1.24
歳入
426k
純利益
-88.45M

Altimmune Inc について

Altimmune Inc is a clinical-stage biopharmaceutical company focused on the development of novel peptide-based therapeutics for the treatment of obesity and liver diseases. The company's lead product candidate, pemvidutide, is a GLP-1/glucagon dual receptor agonist that is being developed for the tre... Altimmune Inc is a clinical-stage biopharmaceutical company focused on the development of novel peptide-based therapeutics for the treatment of obesity and liver diseases. The company's lead product candidate, pemvidutide, is a GLP-1/glucagon dual receptor agonist that is being developed for the treatment of obesity and NASH (non-alcoholic steatohepatitis). In addition, Altimmune is developing HepTcell, an immunotherapeutic designed to achieve a functional cure for chronic hepatitis B virus (HBV). 詳細を表示

セクター
Pharmaceutical Preparations
業界
Pharmaceutical Preparations
ウェブサイト
本社
Wilmington, Delaware, USA
設立
-
Altimmune Inc is listed in the Pharmaceutical Preparations sector of the ナスダック市場 with ticker ALT. The last closing price for Altimmune was US$9.49. Over the last year, Altimmune shares have traded in a share price range of US$ 2.315 to US$ 14.84.

Altimmune currently has 71,070,951 shares in issue. The market capitalisation of Altimmune is US$674.46 million. Altimmune has a price to earnings ratio (PE ratio) of -7.64.

Altimmune (ALT) のオプションフロー概要

全体の流れ

ブルリッシュ

ネットプレミアム

765k

Calls / Puts

380.00%

買い / 売り

214.29%

OTM / ITM

60.00%

Sweeps比率

0.00%

ALT 最新ニュース

Altimmune Announces Third Quarter 2024 Financial Results and Provides a Business Update

Enrollment completed in Phase 2b IMPACT trial of pemvidutide in metabolic dysfunction-associated steatohepatitis (MASH); top-line efficacy data expected in Q2 2025 Successful completion of the...

Altimmune Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GAITHERSBURG, Md., Nov. 11, 2024 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that the Compensation Committee of its Board of...

Altimmune Announces Successful Completion of End-of-Phase 2 Meeting with FDA for Pemvidutide in the Treatment of Obesity

Company and Agency aligned on key efficacy and safety measures to be studied in Phase 3 program Pivotal Phase 3 trials designed to leverage the differentiated attributes of pemvidutide and...

Altimmune to Participate at Two Upcoming Investor Conferences

GAITHERSBURG, Md., Nov. 06, 2024 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that members of the Company’s management team will...

Altimmune to Report Third Quarter 2024 Financial Results and Provide Business Update on November 12, 2024

GAITHERSBURG, Md., Nov. 04, 2024 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that it will report its third quarter 2024...

Altimmune to Present New Data on the Lipidomic Profile in Subjects Treated with Pemvidutide at The Liver Meeting® 2024

GAITHERSBURG, Md., Oct. 15, 2024 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that new data showing reductions of multiple...

Altimmune to Participate in the H.C. Wainwright 8th Annual MASH Virtual Conference

GAITHERSBURG, Md., Oct. 01, 2024 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that its Chief Executive Officer, Vipin Garg...

期間 †前日比前日比 %始値高値安値平均出来高VWAP
12.289931.5413223147.2610.026.9264075208.61934383CS
42.409933.75210084037.1410.026.4529498377.83020556CS
122.449934.50563380287.110.025.8624088087.25443704CS
262.229930.46311475417.3210.025.27529000207.03907181CS
527.0499281.9962.514.842.31554222557.75416837CS
156-1.5401-13.887285843111.0923.492.0928119758.10966532CS
2607.7699436.5112359551.7835.11.4524382449.73054499CS

ムーバー

すべて表示
  • 出来高
  • 値上がり率
  • 値下がり率
銘柄コード株価出来高
MVSTMicrovast Holdings Inc
US$ 0.7951
(340.01%)
1.09B
QUBTQuantum Computing Inc
US$ 2.66
(92.75%)
102.21M
PULMPulmatrix Inc
US$ 3.56
(73.66%)
3.63M
BTCTBTC Digital Ltd
US$ 17.65
(68.10%)
45.37M
NMHINatures Miracle Holding Inc
US$ 0.142
(65.69%)
1.33B
SYRSSyros Pharmaceuticals Inc
US$ 0.359
(-86.85%)
38.53M
GCTKGlucoTrack Inc
US$ 0.36
(-77.06%)
6.58M
PETWag Group Company
US$ 0.21
(-67.98%)
14.68M
GLXGGalaxy Payroll Group Ltd
US$ 6.24
(-56.39%)
2.96M
XFORX4 Pharmaceuticals Inc
US$ 0.2773
(-53.17%)
18.56M
NMHINatures Miracle Holding Inc
US$ 0.142
(65.69%)
1.33B
MVSTMicrovast Holdings Inc
US$ 0.7951
(340.01%)
1.09B
ELABElevai Labs Inc
US$ 0.0247
(31.38%)
541.7M
AGRIAgriFORCE Growing Systems Ltd
US$ 0.0486
(2.53%)
291.83M
NVDANVIDIA Corporation
US$ 146.27
(-1.36%)
191.62M

ALT Discussion

投稿を表示

最近閲覧した銘柄

Delayed Upgrade Clock